[Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer 
with HER2 Mutation]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Human epidermal growth factor receptor 2 (HER2) mutations are key drivers in non-small cell lung cancer (NSCLC).
• Patients with advanced NSCLC and HER2 mutations respond poorly to traditional chemotherapy and immunotherapy.
• Targeted therapies for HER2 are crucial for improving treatment outcomes.

Purpose of the Study:

• To review the biological characteristics of HER2.
• To provide an overview of clinical trials for HER2-targeted therapies in NSCLC.
• To explore research directions for overcoming drug resistance.

Main Methods:

• Literature review of biological characteristics of HER2.
• Analysis of clinical trials for HER2-targeted drugs (monoclonal antibodies, TKIs, antibody-drug conjugates).
• Examination of research on drug resistance mechanisms in NSCLC.

Main Results:

• Pyrotinib and Trastuzumab deruxtecan are approved for advanced NSCLC with HER2 mutations post-standard therapy.
• Novel selective HER2 tyrosine kinase inhibitors (TKIs) are emerging.
• Current approved therapies do not fully meet clinical needs.

Conclusions:

• Future research focuses on combination strategies and precise patient selection for HER2-targeted therapies.
• Investigating resistance mechanisms is essential for developing effective treatments.
• These advancements will support personalized therapy for advanced NSCLC with HER2 mutations.